Evidence map›Paper›PMID 27849593›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

Heparanase is required for activation and function of macrophages.

Lilach Gutter-Kapon, Dror Alishekevitz, Yuval Shaked, Jin-Ping Li, Ami Aronheim, Neta Ilan, Israel Vlodavsky

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 102 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. The Pathophysiological Functions of Heparanases: From Evolution, Structural and Tissue-Specific Perspectives.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Role of heparanase in pulmonary hypertension.Frontiers in pharmacology · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Lilach Gutter-KaponCancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
Dror AlishekevitzDepartment of Cell Biology and Cancer Science, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
Yuval ShakedDepartment of Cell Biology and Cancer Science, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
Jin-Ping LiDepartment of Medical Biochemistry and Microbiology, University of Uppsala, SE-751 05 Uppsala, Sweden.
Ami AronheimDepartment of Molecular Genetics, the Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
Neta IlanCancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
Israel VlodavskyCancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; vlodavsk@mail.huji.ac.il.
Rappaport Family Institute for Research in the Medical Sciences · ILUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emerging role of heparanase in tumor initiation, growth, metastasis, and chemoresistance is well recognized and is encouraging the development of heparanase inhibitors as anticancer drugs. Unlike the function of heparanase in cancer cells, very little attention has been given to heparanase contributed by cells composing the tumor microenvironment. Here we used a genetic approach and examined the behavior and function of macrophages isolated from wild-type (WT) and heparanase-knockout (Hpa-KO) mice. Hpa-KO macrophages express lower levels of cytokines (e.g., TNFα, IL1-β) and exhibit lower motility and phagocytic capacities. Intriguingly, inoculation of control monocytes together with Lewis lung carcinoma (LLC) cells into Hpa-KO mice resulted in nearly complete inhibition of tumor growth. In striking contrast, inoculating LLC cells together with monocytes isolated from Hpa-KO mice did not affect tumor growth, indicating that heparanase is critically required for activation and function of macrophages. Mechanistically, we describe a linear cascade by which heparanase activates Erk, p38, and JNK signaling in macrophages, leading to increased c-Fos levels and induction of cytokine expression in a manner that apparently does not require heparanase enzymatic activity. These results identify heparanase as a key mediator of macrophage activation and function in tumorigenesis and cross-talk with the tumor microenvironment.

Indexed as

Macrophage ActivationAnimalsCarcinoma, Lewis LungCell LineCytokinesGene Expression Regulation, NeoplasticGlucuronidaseHeparanaseMacrophagesMice, Inbred C57BLMice, KnockoutNeoplasm TransplantationSignal TransductionTranscriptional ActivationTranscription FactorsTumor BurdenCytokinesGlucuronidaseHeparanaseTranscription Factorscytokine expressionheparanaseknockout micemacrophagetumor growth

Identifiers

PMID27849593
PMCPMC5137702
OpenAlexW2557183800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.